News

Applied Clinical Trials Online8h
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...
The top reasons Ozempic users are going to the hospital — and the ‘Wild West’ factor that could be driving an unexpected issue
Though popular weight loss jabs like Ozempic and Wegovy have been deemed safe and effective by the FDA, concerning side ...
US FDA accepts Novo Nordisk's application for oral Wegovy for weight loss
The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...
HealthDay on MSN5h
Semaglutide Beneficial in Metabolic Dysfunction-Associated Steatohepatitis, Fibrosis
For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with ...
Managed Healthcare Executive1h
FDA Sets Action Date for Oral Wegovy for Weight Loss
A decision is expected in the fourth quarter of 2025.
Weight-Loss Drugs Have Sent a Shocking Number of People to the Emergency Room, New Study Claims
Semaglutide — known by brand names Ozempic and Wegovy — works in the brain to impact satiety. Over the past two years, the ...
Medical Dialogues18h
Weekly Semaglutide Offers Long-Term Relief: Better Glycaemic Control and Less Insulin in Type 2 Diabetes, Study Finds
Italy: A recent multicentre real-world study supports the long-term effectiveness of once-weekly semaglutide as a valuable ...
Fierce Pharma6h
Madrigal's Rezdiffra, the first-ever MASH drug, beats sales projections for 4 quarters in a row
Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...
Shed pounds before summer for just $50 with this semaglutide weight loss program
Ready to transform your body? It's possible with this program's personalized care, telehealth consultations, and semaglutide ...